DOI: 10.2337/diabetes.55.04.06.db05-1048 © 2006 by the American Diabetes Association CD4+CD25+ Regulatory T-Cells Inhibit the Islet Innate Immune Response and Promote Islet Engraftment
1 Department of Gene and Cell Medicine, and Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York Address correspondence and reprint requests to Dr. Jonathan S. Bromberg, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1104, New York, NY 10029-6574. E-mail: jon.bromberg{at}mountsinai.org
Abbreviations:
IFN, interferon; IL, interleukin; mAb, monoclonal antibody; PE, phycoethrin; TGF, transforming growth factor; TNF- Early islet cell loss is a significant problem in clinical islet cell transplantation. Diverse stress stimuli induce innate immune responses in islets that contribute to ß-cell dysfunction, inflammation, and loss. Here, we show that cytokine-stimulated murine islets express multiple inflammatory chemokines that recruit T-cells and thereby impair islet function in vitro and in vivo. Both nonislet ductal and exocrine elements and the individual islet cellular components contribute to this innate immune response. CD4+CD25+ regulatory T-cells inhibit islet chemokine expression through a cell contact–dependent, soluble factor–independent mechanism and inhibit effector T-cell migration to the islet. Regulatory T-cells can also migrate to stimulated islets. Cotransfer of regulatory T-cells with islets in a transplantation model prevents islet innate immune responses and inflammation and preserves normal architecture and engraftment. Regulatory T-cell inhibition of multiple components of innate immune responses may be a fundamental aspect of their function that influences ischemia-reperfusion injury and adaptive immunity.
|
|
|
||||||||||||||||||||||||||